Ophthalmic manifestations and risk factors for mortality of HIV patients in the post‐highly active anti‐retroviral therapy era: comment

1. Shields CL, Honavar SG, Shields JA, Cater J, Demirci H. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001; 108: 2237– 48. 2. Ruby AJ, Jampol LM, Goldberg MF, Schroeder R, Anderson-Nelson S. Choroidal novascularization associated with choroidal hemangiomas. Arch Ophthalmol 1992; 110: 658–61. 3. Tuncer S, Demirci H, Shields CL, Shields JA. Polypoidal choroidal vasculopathy following photodynamic therapy for choroidal hemangioma. Eur J Ophthalmol 2009; 19: 159–62. 4. Leys AM, Silva R, Inhoffen W, Tatar O. Neovascular growth following photodynamic therapy for choroidal hemangioma and neovascular regression after intravitreous injection of triamcinolone. Retina 2006; 26: 693–7. 5. Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular agerelated macular degeneration in the 2-year anchor study. Retina 2010; 30: 1390–9. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era: comment